tirzepatide versus retatrutide vs Tirzepatide: Best Triple Agonist Guide 2026 Retatrutide or Tirzepatide? Triple vs

1 For the narrower MACE-3 composite of cardiovascular death, heart attack or stroke, there were 27 events in the Retatrutide arm and 23 in the placebo arm, for a hazard ratio of 1.12 (95% CI: 0.64 to 1.96)

Billing Timing: Billing timing is described in different places across the enrollment flow and terms

No oral formulation of retatrutide has been publicly announced or registered in clinical trials as of April 2026 (based on available information from Eli Lilly's published pipeline and ClinicalTrials.gov)

References Bodnaruc, A.M., Prudhomme, D., Blanchet, R

But the shortage has since ended, and the FDA ordered compounders to stop manufacturing mass-compounded GLP-1 drugs in early 2025

If considering grapefruit, be aware it can interact with many medicines including certain statins and calcium channel blockerscheck with your pharmacist or GP before increasing intake